Disclaimer

Actuellement, le système alfapump® n’est pas approuvé aux États-Unis ou au Canada. Aux États-Unis et au Canada, le système alfapump® se trouve actuellement en phase d’examen clinique (étude POSEIDON), et il est étudié sur des patients adultes souffrant d’ascites réfractaires ou récurrentes dues à une cirrhose du foie. Pour de plus amples informations concernant l’étude clinique POSEIDON, cf. www.poseidonstudy.com.
Le traitement DSR (élimination directe de sodium) se trouve encore en phase de développement, et il convient de tenir compte du fait que toute déclaration concernant la sécurité et l’efficacité émane d’examens pré-cliniques et cliniques en cours, ceux-ci n’ayant pas encore été finalisés.
Actuellement, le traitement DSR n’est pas approuvé pour la recherche clinique aux États-Unis ou au Canada. Il n’y a aucun lien entre le traitement DSR et les examens avec le système alfapump® en cours en Europe.

Communiqués de presse

Sequana Medical announces €7.3 million debt financing and provides clinical update

REGULATED INFORMATION – INSIDE INFORMATION 28 July 2020, 07:00 CEST  Cash runway extended into H2 2021 enabling Sequana Medical to reach key near term value inflection points POSEIDON – implants resumed and interim results expected in Q1 2021 (North American pivotal study of the alfapump® in patients with recurrent or refractory ascites due to liver...

Sequana Medical to present at digital Investor Events

Ghent, BELGIUM – 17 June 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the following digital investor events in June:   Kepler Cheuvreux Digital Belgian Life Science Day...

Sequana Medical announces that the results of the alfapump® MOSAIC study have been published in Liver Transplantation  

North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascites   Ghent, BELGIUM – 16 June 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces...

Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders

PRESS RELEASE – 28 May 2020, 06:00 PM CEST REGULATED INFORMATION Ghent, BELGIUM – 28 May 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that all proposed resolutions submitted to the Annual and...

Sequana Medical announces the appointment of Dr Oliver Gödje as Chief Medical Officer

Ghent, BELGIUM – 4 May 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer, with immediate effect. Dr Gödje replaces Gijs Klarenbeek, MD, who remains with Sequana...

Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 28 May 2020

PRESS RELEASE 28 April 2020 07:00 CEST REGULATED INFORMATION   Publication of Annual Report 2019 Ghent, BELGIUM – 28 April 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today invites the holders of securities...

Sequana Medical announces 2019 Full Year Results and 2020 Outlook

PRESS RELEASE 19 MARCH 2020 07:00 CET REGULATED INFORMATION   Continued strong progress in U.S. NASH-related and global heart failure programmes Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast presentation today at 14:00 CET / 09:00 ET   Ghent, BELGIUM – 19 March 2020 –...

Sequana Medical Notice of 2019 Full Year Results and 2020 Outlook

Ghent, BELGIUM – 12 March 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, will announce its results for the full year ended 31 December 2019 and outlook for 2020 on Thursday 19 March 2020. The management team will host...

Transparency Notifications from Shareholders

Regulated Information Ghent, BELGIUM – 21 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of...

Transparency Notifications from Shareholders

Regulated Information Ghent, BELGIUM – 3 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of...
1 2 3 4

Abbonez-vous à nos communiqués de presse

J'accepte le Sequana Medical Privacy Policy

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our
Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close